A review of normal sleep and its disturbances in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 5, Issue 1-2, 1999, Pages 1-17

  Pal, P K ^a   Calne, S ^a   Samii, Ali ^a   Fleming, J A E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Daytime sleepiness; Insomnia; Parasomnia; Parkinson's disease; Sleep; Sleep benefit; Treatment

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AKATHISIA; DREAM; FATIGUE; HUMAN; INSOMNIA; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SLEEP PATTERN; SOMNOLENCE; WAKEFULNESS;

EID: 0032991247     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(99)00011-5     Document Type: Review

References (214)

1. Hobson J. Sleep. 1989;Scientific American Library, New York.
2. Carskadon M.A., Dement W.C. Normal human sleep: an overview. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;16 W.B. Saunders Company, Philadelphia, PA.
3. Kelly D.D. Sleep and dreaming. Kandel E.R., Schwartz J.H., Jessel T.M. Principles of neural science. 1991;792 Appleton and Lange, Norwalk, CT.
4. McCarley R.W. Dreams and the biology of sleep. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;373 W.B. Saunders Company, Philadelphia, PA.
5. Hall C.S., Van de Castle R.L. The content analysis of dreams. 1966;Appleton-Century-Crofts, New York.
6. Williams R.L., Karacan I., Hursch C.J. EEG of human sleep: clinical applications. 1974;Wiley, New York.
7. Bliwise D.L. Sleep in normal aging and dementia. Sleep. 16:1993;40-81.
8. Vitiello M.V., Smallwood R.G., Avery D.H., Pascualy R.A., Martin D.C., Prinz P.A. Circadian temperature rhythms in young and aged men. Neurobiol Aging. 7:1986;97-100.
9. Weitzman E.D., Molin M.L., Czeisler C.A., Zimmerman J.C. Chronobiology of aging: temperature, sleep-wake rhythms and entrainment. Neurobiol Aging. 3:1982;299-309.
10. Kennedy C., Gillin J.C., Mendelson W., et al. Local cerebral glucose utilization in non-rapid eye movement sleep. Nature. 297:1982;325-327.
11. Nakamura R.K., Kennedy C., Gillin J.C., et al. Hypnogenic center theory of sleep: no support from metabolic mapping in monkeys. Brain Res. 268:1983;372-376.
12. Boyle P.J., Scott J.C., Krentz A.J., Nagy R.J., Comstock E., Hoffman C. Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans. J Clin Invest. 93:1994;529-535.
13. Boyar R.M., Rosenfeld R.S., Kapen S., et al. Human puberty: Simultaneous augmented secretion of luteinizing hormone and testosterone during sleep. J Clin Invest. 54:1974;609-618.
14. Sassin J.F., Frantz A.G., Kapen S., et al. The nocturnal rise of human prolactin is dependent on sleep. J Clin Endocrinol Metab. 37:1973;436-440.
15. Takahashi Y., Kipnis D., Daughaday W. Growth hormone secretion during sleep. J Clin Invest. 47:1968;2079-2090.
16. Weitzman E.D., Hellman L. Temporal organization of the 24-h pattern of the hypothalamic-pituitary axis. Ferin M., Halberg F., Richart R.M. Biorhythms and human reproduction. 1974;371 Wiley, New York.
17. Adam K., Oswald I. Protein synthesis, bodily renewal and the sleep-wake cycle. Clin Sci. 65:1983;561-567.
18. Nakanishi H., Sun Y., Nakamura R.K., et al. Positive correlations between cerebral protein synthesis rates and deep sleep in Macaca mulatta. Eur J Neurosci. 9:1997;271-279.
19. Ramm P., Smith C.T. Rates of cerebral protein synthesis are linked to slow wave sleep in the rat. Physiol Behav. 48:1990;749-753.
20. Borbely A.A. A two process model of sleep regulation. Hum Neurobiol. 1:1982;195-204.
21. Feinberg I. Changes in sleep cycle patterns with age. J Psychiatr Res. 10:1974;283-306.
22. Agranoff B.W. Learning and memory: biochemical approaches. Siegel G.J., Albers B.W., Agranoff B., Katzman R. Basic neurochemistry. 1981;801 Little Brown and Co, Boston, MA.
23. Roffwarg H.P., Muzio J.N., Dement W.C. Ontogenic development of the human sleep-dream cycle. Science. 152:1966;604-619.
24. Jouvet M., Delorme R. Locus coeruleus et sommeil paradoxal. C. R. Seances Soc. Biol. Fil. [Paris]. 159:1965;895-899.
25. Bloch V., Hennevin E., Leconte P. Relationship between paradoxical sleep and memory processes. Brazier M.A. Brain mechanisms in memory and learning. 1979;329 Raven Press, New York.
26. Karni A., Tanne D., Rubenstein B.S., Askenasy J.J.M., Sagi D. Dependence on REM sleep of overnight improvement of a perceptual skill. Science. 265:1994;679-682.
27. Crick F., Mitchison G. The function of dream sleep. Nature. 304:1983;111-114.
28. Lavie P. The eccentricity of REM sleep. Lavie P. The enchanted world of sleep. 1996;129 Yale University Press, New Haven, CT.
29. Lavie P., Oksenberg A., Zomer J. It's time, you must wake up now. Perceptual and Motor Skills. 49:1979;447-450.
30. Eastman C.I., Mistlberger R.E., Rechtschaffen A. Suprachiasmatic nuclei lesions eliminate circadian temperature and sleep rhythms in the rat. Physiol Behav. 32:1984;357-368.
31. Pickard G.E., Turek F.W. The suprachiasmatic nuclei: two circadian clocks? Brain Res. 268:1983;201-210.
32. Jouvet M. Recherches sur les structures nerveuses et les méchanismes responsables des différentes phases du sommeil physiologique. Arch Ital Biol. 100:1962;125-206.
33. Laurent J.P., Guerrero F.A. Reversible suppression of ponto-geniculo-occipital waves by localized cooling during paradoxical during paradoxical sleep in cats. Exp Neurol. 49:1975;356-369.
34. Sakai K., Petitjean F., Jouvet M. Effects of ponto-mesencephalic lesions and electrical stimulation upon PGO waves and EMPs in unanaesthetized cats. Electroencephalogr Clin Neurophysiol. 41:1976;49-63.
35. Hobson J.A., Alexander J., Frederickson C.J. The effects of lateral geniculate lesions on phasic electrical activity of the cortex during desynchronized sleep in the cat. Brain Res. 14:1969;607-621.
36. Hobson J.A., McCarley R.W., Wyzinski P.W. Sleep cycle oscillation: Reciprocal discharge by two brainstem neuronal groups. Science. 189:1975;55-58.
37. Nausieda P.A., Weiner W., Kaplan L.R. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol. 5:1982;183-194.
38. van Hilten J.J., Weggeman M., van der Velde E.A., Kerkhof G.A., van Dijk J.G., Roos R.A.C. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm [P-D Sect]. 5:1993;235-244.
39. Factor S.A., McAlarney T., Sanchez-Ramos J.R., Weiner W.J. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord. 5:1990;280-285.
40. Smith M.C., Ellgring H., Oertel W.H. Sleep disturbances in Parkinson's disease patients and spouses. J Am Geriatr Soc. 45:1997;194-199.
41. Aldrich M.S. Parkinsonism. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;783 W.B. Saunders Company, Philadelphia, PA.
42. Dowling G.A. Sleep in older women with Parkinson's disease. J Neurosci Nurs. 27:1995;355-362.
43. Lees A.J., Blackburn N.A., Campbell V.L. The nighttime problems of Parkinson's disease. Clin Neuropharmacol. 11:1988;512-519.
44. Menza M.A., Rosen R.C. Sleep in Parkinson's disease. The role of depression and anxiety. Psychosomatics. 36:1995;262-266.
45. Nausieda P.A. Sleep disorders. Koller W.C. Handbook of Parkinson's disease. 1987;371 Marcel Dekker, New York.
46. Friedman A. Sleep pattern in Parkinson's disease. Acta Med Pol. 21:1980;193-199.
47. Kelly D.D. Disorders of sleep and consciousness. Kandel E.R., Schwartz J.H., Jessel T.M. Principles of neural science. 1991;805 Appleton and Lange, Norwalk, CT.
48. Sharf B., Moskovitz C., Lupton M.D., Klawans H.L. Dream phenomena induced by chronic levodopa therapy. J Neural Transmission. 43:1978;143-151.
49. Moskovitz C., Moses K., Klawans H.L. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 135:1978;669-675.
50. Mahowald M.W., Schenck C.H. REM sleep behavior disorder. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;574 W.B. Saunders Company, Philadelphia, PA.
51. Koller W.C., Silver D.E., Lieberman A. An algorithm for the management of Parkinson's disease. Neurology. 44:(Suppl 10):1994;S1-S52. (abstract).
52. Nausieda P. Sleep in Parkinson's disease. Thorpy M. Handbook of sleep disorders. 1990;719-733 Marcel Dekker, New York.
53. Comella C.L., Tanner C.M., Ristanovic R.K. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol. 34:1993;710-714.
54. Rye D.B., Bliwise D.L. Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. Watts R.L., Koller W.C. Movement disorders: neurologic principles and practice. 1997;687 McGraw-Hill, New York.
55. Schenck C.H., Bundlie S.R., Patterson A.L., Mahowald M.W. Rapid eye movement sleep behavior disorder: a treatable parasomnia affecting older adults. J Au Med Assoc. 257:1987;1786-1789.
56. Schenck C.H., Bundlie S.R., Ettinger M.G., Mahowald M.W. Chronic behavioral disorders of human REM sleep: a category of parasomnia. Sleep. 9:1986;293-308.
57. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology. 46:1996;388-393.
58. Uchiyama M., Isse K., Tanaka K., et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology. 45:1995;709-712.
59. Negro P.J.J., Faber R. Lewy body disease in a patient with REM sleep disorder. Neurology. 46:1996;1493. (letter).
60. Turner R.S., Chervin R.D., Frey K.A., Minoshima S., Kuhl D.E. Probable diffuse Lewy body disesae presenting as REM sleep behavior disorder. Neurology. 49:1997;523-527.
61. Carskadon M.A., Dement W.C., Mitler M.M., Roth T., Westbrook P.R. Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness. Sleep. 9:1986;519-524.
62. Johns M.W. Sleepiness in different situations measured by the Epworth Sleepiness Scale. Sleep. 17:1994;703-710.
63. Johns M.W. Daytime sleepiness, snoring, and obstructive sleep apnea: the Epworth sleepiness scale. Chest. 103:1993;30-36.
64. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 14:1991;540-545.
65. Roth T., Roehrs T.A., Carskadon M.A., Dement W.C. Daytime sleepiness and alertness. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;40 W.B. Saunders Company, Philadelphia.
66. Whitney C.W., Enright P.L., Newman A.B., Bonekat W., Foley D., Quan S.F. Correlates of daytime sleepiness in 4578 elderly persons: the cardiovascular health study. Sleep. 21:1998;27-36.
67. Moldofsky H. Evaluation of daytime sleepiness: a review. Clinics Chest Medicine. 13:1992;417-425.
68. Morewitz J.H. Evaluation of excessive daytime sleepiness in the elderly. J Am Geriatr Soc. 36:1988;324-330.
69. Carskadon M.A. Sleep and alertness. 1989;Raven Press, New York. :53-69.
70. Critchley P.H.S., Malcom G.P., Malcom P.N., Gibb W.R., Arend R., Parkes J.D. Fatigue and melatonin in Parkinson's disease. J Neurol Neurosurg Psychiatry. 54:1991;91-92.
71. ]Marsden C.D., Parkes J.D. Research progress in Parkinson's disease. 1981;Pitman, London. :265-274.
72. Jellinger K.A. Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 14:1991;153-197.
73. Mouret J. Differences in sleep in patients with Parkinson's disease. Electroencephalogr Clin Neurophysiol. 38:1975;653-657.
74. Traczynska-Kubin D., Atzef E., Petre-Quadens O. Le sommeil dans la maladie de Parkinson. Acta Neurol Belgium. 69:1969;727-733.
75. April R.S. Observations on Parkinsonian tremor in all-night sleep. Neurology. 16:1966;720-724.
76. Stern M., Roffwarg H., Duvoisin R. The Parkinsonian tremor in sleep. J Nerv Ment Dis. 147:1968;202-210.
77. Tassinari C.A., Broughton R., Poire R., et al. An electro-clinical study of nocturnal sleep in patients presenting abnormal movements. Electroencephalogr Clin Neurophysiol. 18:1965;95.
78. Fish D.R., Sawyers D., Allen P.J., et al. The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. Arch Neurol. 48:1991;210-214.
79. Askenasy J.J.M., Yahr M.D. Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep. J Neurol Neurosurg Psychiatry. 53:1990;749-753.
80. Bergonzi P., Chiurulla C., Cianchetti C., Tempesta E. Clinical pharmacology as an approach to the study of biochemical sleep mechanisms: the action of L-dopa. Confin Neurol. 36:1974;5-22.
81. Kendel K., Beck U., Wita C., et al. Der Einfluss von L-Dopa auf den Nachtschlaf bei Patienten mit Parkinson-Syndrom. Arch Psychiatr Nervenkr. 216:1972;82-100.
82. Klawans H., Goetz C., Bergen D. L-dopa-induced myoclonus. Arch Neurol. 32:1975;331-334.
83. Nausieda P., Tanner C., Klawans H. Serotonergically active agents in L-dopa-induced psychiatric toxicity reactions. Fahn S., Calne D.B., Shoulson I. Advances in Neurology: Experimental Therapeutics of Movement Disorders. 1983;23 Raven Press, New York. Volume 35.
84. Montplaisir J., Godbout R., Pelletier G., Warnes H. Restless leg syndrome and periodic limb movements during sleep. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;589 W.B. Saunders Company, Philadelphia, PA.
85. Ancoli-Israel S., Kripke D., Klauber M., et al. Periodic leg movements in sleep in community dwelling elderly. Sleep. 14:1991;496-500.
86. Staedt J., Stoppe G., Kogler A., et al. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci. 245:1995;8-10.
87. Montplaisir J., Godbout R., Poirier G., Bedard M.A. Restless legs syndrome and periodic movements in sleep: Physiopathology and treatment with L-dopa. Clin Neuropharmacol. 9:1986;456-463.
88. Linazasoro G., Masso J.F.M., Suarez J.A. Nocturnal akathisia in Parkinson's diaease: treatment with clozapine. Mov Disord. 8:1993;171-174.
89. Lang A., Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology. 37:1987;477-481.
90. van Hilten B., Hoff J.I., Middelkoop H.A.M., et al. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch Neurol. 51:1994;922-928.
91. Goetz C.G., Wilson R.S., Tanner C.M., Garron D.C. Relationships among pain, depression, and sleep alterations in Parkinson's disease. Yahr M.D., Bergmann K.J. Advances in Neurology: Parkinson's disease. 1986;345 Raven Press, New York. Volume 45.
92. Hovestadt A., Bogaard J.M., Meerwaldt J.D., et al. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry. 52:1989;329-333.
93. Vincken W.G., Gauthier S.G., Dollfuss R.E., et al. Involvement of upper-airway muscles in extrapyramidal disorders: A cause of airflow limitation. New Engl J Med. 311:1984;438-442.
94. Bushmann M., Dobmeyer S.M., Leeker L., Perlmutter J.S. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology. 39:1989;1309-1314.
95. Feinsilver S.H., Friedman J.H., Rosen J.M. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry. 49:1986;964.
96. 2 responsiveness in Parkinson's disease: Evidence for a role of dopamine in respiratory control. Am Rev Respir Dis. 131:1985;A297.
97. Apps M.C.P., Sheaff P.C., Ingram D.A., et al. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry. 48:1985;1240-1245.
98. Hardie R.J., Efthimiou J., Stern G.M. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry. 49:1986;1326.
99. Jennum P., Sjol A. Self-assessed cognitive function in snorers and sleep apneics. Eur Neurol. 34:1994;204-208.
100. Mosko S., Zetin M., Glen S., et al. Self-reported depressive symptomatology, mood ratings and treatment outcome in sleep disorders patients. J Clin Psychol. 45:1989;51-60.
101. Rodin J., McAvay G., Timko C. A longitudinal study of depressed mood and sleep disturbances in the elderly adults. J Gerontol Psyc Sci. 43:1988;45-53.
102. Kupfer D.J., Foster F.G. Interval between onset of sleep and rapid-eye-movement sleep as an indicator of depression. Lancet. 2:1972;684-686.
103. Henderson R., Kurlan R., Kersum J.M., Como P. Preliminary examination of the co-morbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 4:1992;257-264.
104. Mayeux R. Mental state. Koller W.C. Handbook of Parkinson's disease. 1987;127 Marcel Dekker, New York.
105. Huber S.J., Freidenberg D.L., Paulson G.W., Shuttleworth E.C., Christy J.A. The pattern of depressive symptoms varies with progression of Parkinson's disease. J Neurol Neurosurg Psychiatry. 53:1990;275-278.
106. Melamed E. Neurobehavioral abnormalities in Parkinson's disease. Watts R.L., Koller W.C. Movement disorders: neurologic principles and practice. 1997;257 McGraw-Hill, New York.
107. Kostic V.S., Susic V., Przedborski S., et al. Sleep EEG in depressed and nondepressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci. 3:1991;176-179.
108. Starkstein S.E., Preziosi T.J., Robinson R.G. Sleep disorders, pain and depression in Parkinson's disease. Eur Neurol. 31:1991;352-355.
109. De Keyser J., Ebinger G., Vauquelin G. Evidence for a widespread dopaminergic innervation of the human cerebral neocortex. Neurosci Lett. 104:1989;281-285.
110. Bo P., Ongini E., Giorgetti A., Savoldi F. Synchronization of the EEG and sedation induced by neuroleptics depend upon blockade of both D1and D2 dopamine receptors. Neuropharmacol. 27:1988;799.
111. Ongini E., Caporali M.G., Massotti M. Stimulation of dopamine D-1 receptors by SKF 38393 includes EEG desynchronisation and behavioral arousal. Life Sci. 37:1985;2327-2333.
112. Trampus M., Ferri N., Monopoli A., Ongini E. The dopamine D1 receptor is involved in the regulation of REM sleep in the rat. Eur J Pharmacol. 194:1991;189-194.
113. Trampus M., Ongini E. The D1 dopamine receptor antagonist SCH 23390 enhances REM sleep in the rat. Neuropharmacology. 10:1990;889-893.
114. Cianchetti C. Dopamine agonists and sleep in man. Wauquier A., Gaillard J.M., Monti J.M., Radulovacki M. Sleep: neurotransmitters and neuromodulators. 1985;121 Raven Press, New York.
115. Kafi S., Gaillard J. Brain dopamine receptors and sleep in the rat: effects of stimulation and blockade. Eur J Pharmacol. 38:1976;357-363.
116. Nicholson A.N., Pascoe P.A. Dopaminergic transmission and the sleep-wakefulness continiuum in man. Neuropharmacology. 29:1990;411-417.
117. Bergonzi P., Chiurulla C., Gabi D., Mennini G., Pinto F. L-dopa plus dopa decarboxylase inhibitor: sleep organization in Parkinson's syndrome before and after treatment. Acta Neurol Belgium. 75:1975;5-10.
118. Bergonzi P., Bianco A., Cognossi M., Mennini G. Valutazione emodinamicapsicometrica et elettroencefalografica della terapia con Levo-Dopa in soggetti da cirrosi epatica. Patol Nerv Ment. 11:1974;1-8.
119. Fram D.H., Murphy D.L., Goodwin F.K., et al. L-dopa and sleep in depressed patients. Psychophysiology. 7:1971;316.
120. Greenberg R., Pearlman C.A. L-dopa parkinsonism and sleep. Psychophysiology. 7:1971;314-315.
121. Kales A., Ritvo E.R., Preston T.A., Scharf M.B., Tau T.L. Effects of prolonged administration of L-dopa on the sleep patterns of autistic children. Psychophysiology. 9:1972;89.
122. Schmidt H.S., Knopp W. Sleep in Parkinson's disease: the effect of L-dopa. Psychophysiology. 9:1972;88-89.
123. Wyatt R.J., Chase T.N., Scott J., Snyder F., Engelman K. Effect of L-Dopa on the sleep of man. Nature. 228:1970;999-1001.
124. Askenasy J.J.M., Yahr M.D. Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study. Neurology. 35:1985;527-532.
125. Jansen E.N.H., Meerwaldt J.D. Madopar HBS in Parkinsonian patients with nocturnal akinesia. Clin Neurol Neurosurg. 90:1988;35-39.
126. Leeman A.L., O'Neill C.J.A., Nicholson P.W., et al. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol. 24:1987;637-643.
127. Lees A.J. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in parkinson's disease. Eur Neurol. 27(Suppl 1):1987;126-134.
128. Lesser R.P., Fahn S., Snider S.R., Cote L.J., Isgreen W.P., Barrett R.E. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 29:1979;1253-1260.
129. Sweet R.D., McDowell F.H. Five years treatment of Parkinson's disease with levodopa. Ann Intern Med. 83:1975;456-463.
130. Crismon M.L. Insomnia. Koda-Kimble M.A., Young L.Y. Applied therapeutics: the clinical use of drugs. 1992;1 Applied Therapeutics, Vancouver, WA.
131. Lacy C., Armstrong L.L., Ingrim N., Lance L.L. Drug information handbook. 1995;Lexi-Comp, Hudson, OH.
132. Ashton H. The effect of drugs on sleep. Cooper R. Sleep. 1994;175-211 Chapman and Hall, New York.
133. Sharpley A.L., Cowen P.J. Effect of Pharmacologic Treatments on the Sleep of Depressed Patients. Biol Psychiatry. 37:1995;85-98.
134. Kay D.C., Blackburn A.B., Buckingham J.A., Karacan I. Human pharmacology of sleep. Williams R.L., Karacan I. Pharmacology of sleep. 1976;83 John Wiley & Sons, New York.
135. Gillin J.C., Sutton L., Ruiz C., et al. Dose dependent inhibition of REM sleep in normal volunteers by biperiden, a muscarinic antagonist. Biol Psychiatry. 30:1991;151-156.
136. Sitaram N., Moore A., Gillin J.C. Experimental acceleration and slowing of REM sleep ultradian rhythm by cholinergic agonist and antagonist. Nature. 274:1978;490-492.
137. Zung W. SDS. Self-rating depression scale. Guy W. ECDEN assessment manual for psychopharmacology. 1976;333 EDN, Rockville, MD.
138. Currie L.J., Bennett J.P., Harrison M.B., Trugman J.M., Wooten G.F. Clinical correlates of sleep benefit in Parkinson's disease. Neurology. 48:1997;1115-1117.
139. Comella C.L., Bohmer J., Stebbins G.T. Sleep benefit in Parkinson's disease. Neurology. 45:((suppl 4)):1995;A286. (abstract).
140. Marsden C.D., Parkes J.D., Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. Marsden C.D., Fahn S. Neurology, Vol. 2: Movement Disorders. 1982;96 Butterworth, London.
141. Merello M., Hughes A., Colosimo C., Hoffman M., Starkstein S., Leiguarda R. Sleep benefit in Parkinson's disease. Mov Disord. 12:1997;506-508.
142. Parkes J.D. Variability in Parkinson's disease: clinical aspects, causes and treatment. Acta Neurol Scand. 68 (Suppl 95):1983;27-35.
143. Clarke E.C., Feinstein B. The on-off effect in Parkinson's disease treated with levodopa with remarks concerning the effect of sleep. Adv Exp Med Biol. 90:1977;175-182.
144. Hardie R.J. Levodopa-related motor fluctuations. Stern G.M. Parkinson's disease. 1990;559 Johns Hopkins University Press, Baltimore, MD.
145. Hogl B.E., Gomez-Arevalo G., Garcia S., et al. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology. 50:1998;1332-1339.
146. Kales A., Ansel R.D., Markham C.H., Scharf M.B., Tan T. Sleep in patients with Parkinson's disease and normal subjects prior to and following levodopa administration. Clin Pharmacol Ther. 12:1971;397-406.
147. Wilson W.P., Nashold B.S., Green R.L. Studies of the cortical and subcortical electric activity during sleep of patients with dyskinesias. 1969;Churchill Livingstone, Edinburgh. :160-164.
148. Comella C.L., Tanner C.M., Ristanovik R.K. Sleep disturbancs and hallucinations in Parkinson's disease: results of quantitive sleep studies. Ann Neurol. 30:1991;295.
149. Hauri P. Treating psychophysiologic insomnia with biofeedback. Arch Gen Psychiatry. 38:1981;752-758.
150. Zarcone V.P.J. Sleep hygiene. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;542 W.B. Saunders Company, Philadelphia, PA.
151. Bootzin R.R., Perlis M.L. Nonpharmacologic treatments of insomnia. J Clin Psychiatry. 53:1992;37-41.
152. Stepanski E.J. Behavioral therapy for insomnia. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;535 W.B. Saunders Company, Philadelphia, PA.
153. Spielman A.J., Saskin P., Thorpy M.J. Treatment of chronic insomnia by restriction of time in bed. Sleep. 10:1987;45-56.
154. Lichstein K.L., Fischer S.M. Insomnia. Hersen M., Bellack A.S. Handbook of clinical behavior therapy with adults. 1985;319-352 Plenum Press, New York.
155. Czeisler C.A., Richardson G.S., Coleman R.M., et al. Chronotherapy: resetting the circadian clock of patients with delayed sleep phase insomnia. Sleep. 4:1981;1-21.
156. Czeisler C.A., Kronauer R.E., Allen J.S., et al. Bright light induction of strong (type 0) resetting of the human pacemaker. Science. 244:1989;1328-1333.
157. Stocchi F., Barbato L., Nordera G., Berardelli L., Ruggieri S. Sleep disorders in Parkinson's disease. J. Neurol. 245:(Suppl 1):1998;S15-S18.
158. Askenasy J.J.M., Yahr M.D. Suppression of REM rebound by pergolide. J Neural Transm. 59:1984;151-159.
159. Olson W.L., Gruenthal M., Mueller M.E., Olson W.H. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Amer J Medicine. 102:1997;60-66.
160. Olson W.L., Gruenthal M., Mueller M.E., Olson W.H. Gabapentin for parkinsonism: a double-blind, placebo-controlled crossover trial. Mov Disord. 11:1996;597-598.
161. Chana P., de Marins A., Barrientos N. Gabapentin and motor fluctuations in Parkinson's disease. Mov Disord. 12:1997;608.
162. Rao M.L., Clarenbach P., Vahlensieck M., Kratzschmar S. Gabapentin augments whole blood serotonin in healthy young men. J Neural Transmission. 73:1988;129-134.
163. Kupfer D.J., Reynolds C.F. Mangement of insomnia. New Engl J Med. 336:1997;341-346.
164. Balter M.B., Uhlenhuth E.H. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry. 53:1992;34-39.
165. Linsen S.M., Zitman F.G., Breteler M.H. Defining benzodiazepine dependence: the confusion persists. Eur Psychiatry. 10:1995;306-311.
166. Nowell P.D., Mazumdar S., Buysse D.J., Dew M.A., Reynolds C.F., Kupfer D.J. Benzodiazepines and Zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. J Au Med Assoc. 278:1997;2170-2177.
167. Hoehns J.D., Perry P.J. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharmacy. 12:1993;814-828.
168. Scharf M.B., Roth T., Vogel G.W., Walsh J.K. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 55:1994;192-199.
169. Shaw S.H., Curson H., Coquelin J.P. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res. 20:1992;150-161.
170. Schatzberg A.F., Cole J.O., De Battista C. Hypnotics. Manual of clinical psychopharmacology. 1997;267 American Psychiatric Press, Washington, DC.
171. Fairweather D.B., Kerr J.S., Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol. 43:1992;597-601.
172. Ganzoni E., Santoni J.P., Chevillard V., Sebille M., Mathy B. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J Int Med Res. 23:1995;61-73.
173. Monti J.M., Attali P., Monti D., Zipfel A., de la Giclais B., Morselli P.L. Zolpidem and rebound insomnia-a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry. 27:1994;166-175.
174. Shelton P.S., Hocking L.B. Zolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother. 31:1997;319-322.
175. Lobo B.L., Greene W.L. Zolpidem: distinct from Triazolam? Ann Pharmacother. 31:1997;625-632.
176. Lader M. Zopiclone: is there any dependence and abuse potential? J Neurol. 244:(Suppl 1):1997;S18-S22.
177. Goa K.L., Heel R.C. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs. 32:1986;48-65.
178. Schatzberg A.F., Cole J.O., De Battista C. Antianxiety Agents. Manual of clinical psychopharmacology. 1997;223 American Psychiatric Press, Washington, DC.
179. Feldman R.S., Meyer J.S., Quenzer L.F. Sedative-hypnotic and anxiolytic drugs. Principles of neuropsychopharmacology. 1997;673 Sinauer Associates, Sunderland, MA.
180. Treves T.A., Paleacu D., Korczyn A.D. Treatment of Depression in Parkinson's Disease. Koller W.C., Paulson G. Therapy of Parkinson's disease. 1995;513 Marcel Dekker, New York.
181. Cohen L.J. Rational Drug Use in the Treatment of Depression. Pharmacotherapy. 17:1997;45-61.
182. Hodder J. Shy Drager Syndrome. Axon. 18:1997;75-79.
183. Schatzberg A.F., Cole J.O., De Battista C. Antidepressants. Manual of clinical psychopharmacology. 1997;31 American Psychiatric Press, Washington, DC.
184. Asnis G. Parkinson's disease, depression and ECT: a review and case study. Am J Psychiatry. 134:1977;191-195.
185. Lebensohn Z., Jenkins R.B. Improvement of parkinsonism in depressed patient with ECT. Am J Psychiatry. 132:1975;283-285.
186. Schenck C.H., Mahowald M.W. Polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with the REM sleep behavior disorder (RBD): Sustained clonazepam efficacy in 89.5% of 57 treated patients. Clev Clin J Med. 57:1990;S10-S24.
187. Factor S.A., Molho E.S., Podskalny G.D., Brown D. Parkinson's disease: drug-induced psychiatric states. Weiner W.J., Lang A.E. Advances in neurology: behavioral neurology of movement disorders. 1995;115 Lippincot-Raven, Philadelphia, PA.
188. Waters C.H. Managing the late complications of Parkinson's disease. Neurology. 49 (Suppl. 1):1997;S49-S57.
189. Friedman J., Lannon M. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology. 39:1989;1219-1221.
190. Greene P., Cote L., Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Narabayashi H., Nagatsu H., Yanagisawa N., Mizuno Y. Parkinson's disease: from basic research to treatment. Advances in Neurology. 1993;703 Raven Press, New York. Volume 60.
191. Lew M.F., Waters C.H. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc. 41:1993;669-671.
192. Rabey J.M., Treves T.A., Neufeld M.Y., Orlov E., Korczyn A.D. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology. 45:1995;432-434.
193. Ruggieri S., De Pandis M.F., Bonamartini A., Vacca L., Stocchi F. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol. 20:1997;204-209.
194. Wolters E.C., Hurwitz T.A., Mak E., et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 40:1990;832-834.
195. Wong DT, Calligaro DO, Bymaster FP, Moore NA, Seeman P. Preclinical pharmacology of olanzapine: a novel antipsychotic agent. Presented at the Ninth World Congress of Psychiatry; June 6-12, 1993; Rio de Janerio, Brazil.
196. Wolters E, Tuynman-Qua HG. Dopaminometic psychosis: the role of atypical neuroleptics. In: Alberta R, Ochoa JJ, editors. Pautas actualis en el tratamiento medico y quirurgico de la enfermedad de Parkinson. Barcelona: Inter-Congres, 1995:257-268.
197. Wolters E.C., Jansen E.N.H., Tuynman-Qua H.G., Bergmans P.L.M. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 47:1996;1085-1087.
198. Zoldan J., Friedberg G., Weizman A., Melamed E. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-dopa therapy in advanced Parkinson's disease. Battisin L., Scarlato G., Caraceni T., Ruggieri S. Advances in Neurology: Parkinson's disease. 1996;541 Lippincot-Raven, Philadelphia, PA. Volume 60.
199. Zoldan J., Friedberg G., Livneh M., Melamed E. Zolpidem and rebound insomnia-a double-blind, controlled polysomnographic study in chronic insomniac patients. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 antagonist. Neurology. 45:1995;1305-1308.
200. Zoldan J., Friedberg G., Goldberg-Stern H., Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet. 341:1993;562-563.
201. Rich S.S., Friedman J.H., Ott B.R. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psych. 56:1995;556-559.
202. Boghen D. Successful treatment of restless legs with clonazepam. Ann Neurol. 8:1980;341.
203. Bonnet M.H., Arand D.L. The use of triazolam in older patients with periodic leg movements, fragmented sleep, and daytime sleepiness. J Gerontol. 45:1990;139-144.
204. Matthews W.B. Treatment of the restless legs syndrome with clonazepam. Br Med J. 281:1979;751.
205. Mitler M.M., Browman C.P., Menn S.J., et al. Nocturnal myoclonus: Treatment efficacy of clonazepam and temazepam. Sleep. 9:1986;385-392.
206. Moldofsky H., Tullis C., Quance G., Lue F.A. Nitrazepam for periodic movements in sleep (sleep-related myoclonus). Can J Neurol Sci. 13:1986;52-54.
207. Oshtory M.A., Vijayan N. Clonazepam treatment of insomnia due to sleep myoclonus. Arch Neurol. 37:1980;119-120.
208. Brodeur C., Montplaisir J., Marinier R., Godbout R. Treatment of RLS and PLMS with L-dopa: A double-blind controlled study. Neurology. 35:1988;1845-1848.
209. Hening W.A., Walters A., Kavey N., et al. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology. 36:1986;1363-1366.
210. Trzepacz P.T., Violette E.J., Sateia M.J. Response to opioids in three patients with restless legs syndrome. Am J Psychiatry. 141:1984;993-995.
211. Zucconi M., Coccagna G., Petronelli R., et al. Nocturnal myoclonus in restless legs syndrome: Effect of carbamazepine treatment. Funct Neurol. 4:1989;263-271.
212. Bastani B., Westervelt F.B. Effectiveness of clonidine in alleviating the symptoms of "restless legs" Am J Kidney Dis. 10:1987;326. (letter).
213. Handwerker J., Palmer R.F. Clonidine in the treatment of "restless leg" syndrome. New Engl J Med. 313:1985;1228-1229.
214. Guilleminault C., Flagg W. Effect of baclofen on sleep-related periodic leg movements. Ann Neurol. 15:1984;234-239.